China’s rise as a major center of drug development represents one of the most consequential shifts in the global life sciences landscape in a generation. From the patient perspective, a key policy question is how China’s expanding capacity, spanning follow-on products that are based on an approved drug to first-in-class innovation, can be integrated into regulatory frameworks to ensure timely and equitable access to medicines.
JAMA (Journal of the American Medical Association) published a clinical update in Research Highlights on 21 Apr 2026.
The item focuses on The Geography of Pharmaceutical Innovation.
Review the original article for the full source wording and details.